The Netherlands is battling two epidemics of the novel coronavirus: one against its existing variants, in which cases are declining, and "another epidemic involving the U.K. variant, in which infections are increasing," the Dutch National Institute for Public Health and the Environment said in a situation report released Tuesday.

The so-called U.K. variant, first identified in England last September, has caused a massive jump in COVID-19 hospitalizations in the United Kingdom and Ireland.

In the Netherlands, government officials said they were "gravely concerned about the U.K. variant." Over the weekend they introduced a nighttime curfew which has sparked riots.

Over the last two weeks, the Netherlands has reported an 11.7% positivity rate for COVID-19 tests.

ABC News’ Christine Theodorou contributed to this report.

The worldwide number of people who have been diagnosed with COVID-19 surpassed 100 million on Tuesday, according to real-time data collected by Johns Hopkins University. The United States accounts for over 25 million of those cases.

For perspective, only 14 countries in the world have populations over 100 million, according to the latest data from the World Bank Group.

The grim milestone comes just over one year since the first COVID-19 case was confirmed in Wuhan, China, on Dec. 31, 2019.

The number of people who have died from COVID-19 in the United Kingdom has surpassed 100,000, British Prime Minister Boris Johnson announced Tuesday.

"It's hard to compute the sorrow contained in that grim statistic," Johnson said.

More than 35,000 people in the U.K. are hospitalized with COVID-19, which is "substantially" above the peak in April, according to Johnson.

The number of people testing positive for the disease remains high but is decreasing slowly, with 20,089 new cases reported Tuesday, according to Johnson.

ABC News’ Christine Theodorou contributed to this report.

This year's Boston Marathon will be held on Oct. 11, if road races are allowed in Massachusetts' reopening plan at that time, according to the Boston Athletic Association.

A virtual race will also be offered as an option to runners.

"While it was of course the right thing to do, canceling the 2020 Boston Marathon for the first time in its 124-year history was one of the hardest announcements to make," Boston Mayor Marty Walsh said in a statement Tuesday.

"Today, I'm filled with hope, as we set our sights on October for the running of the 125th Boston Marathon," he added. "We have a ways to go before we're out of the woods, but guided by sound judgment and the advice of our public health experts, I am hopeful that we'll get to enjoy the return of one of Boston's most storied traditions this fall."

ABC News' Leo Mayorga contributed to this report.

American biotechnology company Regeneron Pharmaceuticals announced Wednesday that its cocktail of two monoclonal antibodies held up in laboratory experiments against new variants of the novel coronavirus first identified in the United Kingdom and South Africa.

Monoclonal antibodies are synthetic versions of our natural antibody defense to infection. They are being studied as a way to both treat and prevent COVID-19 infection, with promising results. But unlike vaccines, which are thought to offer broader protection, some scientists have been worried that this type of therapy would be less effective against newly emerging variants of the virus.

Wednesday's announcement is good news for Regeneron's monoclonal antibody treatment, REGEN-COV, though the data is still preliminary and currently under peer review.

Regeneron scientists as well as researchers at Columbia University in New York City have each independently confirmed that the casirivimab and imdevimab antibody cocktail successfully neutralized both the U.K. and South Africa variants when tested against them, according to a company press release.

REGEN-COV has not yet been tested against another variant that was first identified in Brazil. However, Regeneron said the two-antibody cocktail "is expected to remain similarly potent" based on some resemblance which the Brazil variant bears to the South Africa strain. The company said it is pursuing further confirmatory research.

It's the latest piece of promising news about the efficacy of monoclonal antibodies as treatment for COVID-19. On Tuesday, American pharmaceutical firm Eli Lilly and Company announced that a combination of two monoclonal antibodies, bamlanivimab and etesevimab, was found to be effective in COVID-19 patients at high risk of severe infection, reducing the risk of hospitalization and death by 70%, according to the results of a final-stage trial.

That same day, Regeneron announced its antibody cocktail had shown positive initial results in prophylactic use -- that is, helping ward off COVID-19 in those who may have been exposed to the virus. Regeneron’s chief scientific officer, Dr. George Yancopoulos, said he hopes the drug "may be able to help break this chain" of active infection and transmission.

Last Thursday, Eli Lilly released data showing bamlanivimab may help prevent disease and stop outbreaks among residents and staff of long-term care facilities.

ABC News' Sasha Pezenik contributed to this report.